<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined IL-6 levels in the cerebrospinal fluid (CSF) of patients clinically diagnosed with Alzheimer-type <z:hpo ids='HP_0000726'>dementia</z:hpo> (ATD) and with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VD) and of age-matched <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="1" pm="."><plain>The IL-6 levels in the CSF of ATD, but not VD patients, were significantly decreased </plain></SENT>
<SENT sid="2" pm="."><plain>In the early <z:hpo ids='HP_0003674'>onset</z:hpo> ATD patients (disease <z:hpo ids='HP_0003674'>onset</z:hpo> &lt; 65 years), IL-6 levels were reduced to 21% of the control level </plain></SENT>
<SENT sid="3" pm="."><plain>The IL-6 levels in the CSF were not associated with the severity of the <z:hpo ids='HP_0000726'>dementia</z:hpo> or the duration of the disease since the identification of the first symptoms </plain></SENT>
</text></document>